Goldman Sachs Maintains Buy on CareDx, Raises Price Target to $14
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Matthew Sykes has maintained a Buy rating on CareDx (NASDAQ:CDNA) and increased the price target from $10 to $14.
May 13, 2024 | 3:40 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Goldman Sachs has reaffirmed its Buy rating on CareDx and raised the price target from $10 to $14, indicating a positive outlook on the stock.
The upgrade in price target by a reputable analyst like Goldman Sachs typically signals a strong conviction in the company's future performance and growth prospects. This can lead to increased investor confidence and potentially drive up the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100